Market Newsdesk

PARIS and MONTREAL, Dec. 14, 2020 (GLOBE NEWSWIRE) — Servier, an international pharmaceutical company, announces the opening of a worldwide Artificial Intelligence (AI) Hub in Montreal, in partnership with Centech, a deep-tech business incubator recognized as one of the most successful university incubators in the world.

The creation of Servier’s Artificial Intelligence Hub occurs within the framework of the ambitious digital transformation project undertaken by the Group, as they are convinced of the key position that digitalization must have in their activities, and the growing role of artificial intelligence in serving patients’ health needs and in the functioning of organizations.

The hub will be the first international AI unit for the Servier Group. It will be set up by Centech within their existing open innovation platform, Collision Lab, and will complete the creation of a data team across the group, aimed in particular at developing initiatives in the field of AI.

Servier’s Artificial Intelligence Hub will be specialized in the area of pharmaceutical Research and Development. The advantages of Centech’s ecosystem, and its recognized expertise in medical technology and the application of AI solutions, will allow the teams to speed up the discovery, development, and deployment of new therapeutic solutions for patients.

The creation of Servier’s worldwide Artificial Intelligence Hub was lauded by Quebec’s minister for Economy and Innovation, Pierre Fitzgibbon.

“I welcome Servier’s decision to have chosen Montréal to establish its Hub in Artificial Intelligence. This decision confirms Québec’s leadership in the field of Artificial Intelligence applied to healthcare. I am convinced that the collaboration between Servier and Centech will pave the way for the accomplishment of many promising projects in healthcare, for the benefit of patients from Québec, Canada and across the world. “said Minister Fitzgibbon.

Speeding up the development of therapeutic solutions

The aim of the hub will be above all to promote, establish and maintain interactions and collaborations between players in the local ecosystem and Servier’s international Research and Development teams. The hub will also accelerate the adoption and adaptation of Artificial Intelligence tools in the Servier Group’s R&D activities and establish links with Canadian and American regulatory bodies in the area of AI. In addition, Servier’s Artificial Intelligence Hub will also create a presence and a business intelligence function in the ecosystem of Montreal, among the most reputed and dynamic in the world in the AI field.

The creation of this hub represents a major investment for Servier and could reach almost 3 million dollars by 2022, allowing the financing of partnership and/or codevelopment deals with local startups, as well as potential recruitment of experts. The dynamism, the reach, the accessibility, and the attractiveness of Montreal’s ecosystem, which is unique in the world, convinced Servier to choose Canada, and more particularly Quebec, as the location for its first hub dedicated to AI.

This hub, set up at the heart of an ecosystem which is unique in the world, will allow us to explore new technologies which could contribute to improving the performance of the Group in all its areas of activity, and thus support its commitment to therapeutic progress for the good of patients stated Virginie Dominguez, Chief Digital Officer of the Servier Group. The structuring of a team dedicated to artificial intelligence, and the creation of this Hub, are a powerful testimonial to Servier’s commitment in this field, which could eventually support research, development, production, and availability to patients of new therapeutic solutions.

For Claude Bertrand, Executive VP for R&D in the Servier Group,  Artificial intelligence opens up wonderful perspectives for patients, in particular in detection, prevention, and diagnosis of diseases. It should significantly improve the productivity and efficiency of R&D by influencing all the steps in drug discovery. Our Group has already begun a movement towards data and digitalization, but this Hub will allow us to speed up this transformation by collaborating with one of the world’s best ecosystems.

Montréal: an ecosystem for artificial intelligence that is unique in the world

Stéphane Paquet, CEO of Montréal International: “Greater Montréal is known worldwide for its excellence in artificial intelligence and life sciences, two ecosystems colliding more every day. We are pleased to welcome the Servier’s Artificial Intelligence Hub, which will showcase Montréal’s know-how in these fields. This collaboration with Centech will certainly help to make Greater Montréal even more attractive in this strategic sector.”

For its Artificial Intelligence Hub, Servier chose Centech, a world-caliber incubator which can provide a support environment for artificial intelligence solutions, fostering competition between private and academic entities. Centech hosts businesses with high potential in the area of health and medical technology, and also businesses in the digital and new technology sector, whose experience in developing digital solutions is renowned worldwide. For Centech, this partnership fits perfectly with an open innovation development strategy for large companies wishing to develop technology projects, particularly those using AI.

According to Richard Chénier, General Manager of Centech,  As an incubator specializing in deep-tech which supports, in particular, startups in the medical field, we are very proud to have been chosen by a major international player in pharmaceuticals such as Servier. By joining our open innovation platform Collision Lab, the Servier Group will benefit from the technological expertise of our companies specialized in medical technologies, and of our ecosystem which promotes the integration of artificial intelligence solutions. 

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
More information: www.servier.com

Follow us on Social Media: 
https://www.linkedin.com/company/servier/
https://www.facebook.com/Servier/
https://twitter.com/servier

Press contacts:

Sonia Marques:	[email protected] – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau:	[email protected] – Tel. +33 (0)1 55 46 16 / +33 6 79 56 75 96

About Centech
Dedicated to high-tech (deeptech) companies with high growth potential, Centech is a world-class business incubator based in Montreal.

Centech is a non-profit organization open to everyone and offers two support programs for startups: the Acceleration program (12 weeks), then the strongest potentials are selected to get into the Propulsion program (24 months).

Since 2018, Centech has its own open innovation platform, Collision Lab, where big corporations are supported to integrate technology projects thanks to the agility of startups and the entrepreneurial ecosystem.

Centech performs particularly well in the fields of medical technology, manufacturing, telecoms and microelectronics and other intelligent objects.

In 2019, Centech was recognized by UBI Global as one of the most successful university incubators in the world.

More information: https://centech.co/en/

Follow us on Social Media:
https://www.linkedin.com/company/centech-mtl
https://www.facebook.com/CentechMtl/
https://twitter.com/CentechMTL

Press contact:

Sophie Reinach : [email protected] – Phone number. +1 514 554 -1746

About Montréal International (www.montrealinternational.com)
Montréal International is a non-profit organization funded by the private sector, the governments of Canada and Québec, the Communauté métropolitaine de Montréal and the City of Montréal. Its mandate is to attract and retain foreign investment (companies and startups), international organizations, skilled workers and international students to Greater Montréal by providing support services tailored to their needs.

Press contact:

Céline Clément : [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7986527-ab75-4554-817f-4a8cdddc325e

Click


here


to join the case

LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Turquoise Hill Resources Ltd. (“Turquoise” or “the Company”) (NYSE: TRQ) investors that acquired securities between July 17, 2018 and July 31, 2019.  

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

Turquoise announced in a press release on February 26, 2019 that, while “the [Oyu Tolgoi] project cost was expected to remain within the $5.3 billion budget,” a review had determined that “there was an increasingly likely risk of a further delay to sustainable first production beyond Q3‘21.” Turquoise Hill attributed the “likely risk” to productivity setbacks in completing Shaft 2 and “challenging ground conditions that have had a direct impact on the project’s critical path.”

Turquoise’s share price fell $0.27, or approximately 13%, on this news, to close at $1.83 per share on February 27, 2019, which injured investors.

Then, Turquoise Hill announced on July 15, 2019 that sustainable first production from the underground development of Oyu Tolgoi would henceforth be delayed by another 9 to 21 months until May 2022 to June 2023. Turquoise also stated that “the development capital spend for the project may increase by $1.2 to $1.9 billion over the $5.3 billion previously disclosed.”

Turquoise’s share price fell $0.47, or 44%, on this news, to close at $0.60 per share on July 16, 2019, which injured investors further.

Then, after the market closed on July 31, 2019, Turquoise disclosed that it had taken a $600 million impairment charge and a significant “deferred income tax recognition adjustment”, which was tied to the Oyu Tolgoi project, and that it had suffered a loss in the second quarter of 2019.

Turquoise’s share price fell $0.05, or over 8%, on this news, to close at $0.53 per share on August 1, 2019, which injured investors further.

It is alleged in the complaint that throughout the Class Period, Turquoise made statements that were materially misleading and/or false, as well as failed to disclose material adverse facts about the Turquoise’s operations, business, and prospects. Specifically, Turquoise failed to disclose to investors: (1) that the progress of underground development of Oyu Tolgoi was not proceeding as planned; (2) that there were significant undisclosed underground stability problems that called into question the projected cost and timing of production and the design of the mine; (3) Turquoise publicly released estimates of the date of completion, cost, and dates for production from the underground mine were not realizable; (4) the development capital that was required for the Oyu Tolgoi underground development would cost significantly more than a billion dollars in excess of what Turquoise had represented; (5) Further financing and/or equity would be required for Turquoise to complete the project; and (6), Turquoise’s positive statements about their business, operations, and prospects were materially misleading and/or lacked a reasonable basis, as a result of the foregoing.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) — 2nd Watch, a leading provider of cloud migration and managed cloud services, announces it has received the 2020 Customer Satisfaction Award from Channel Partner Insight. 2nd Watch received the award last week during a virtual ceremony conducted by Channel Partner Insight.

The Channel Innovation Awards powered by Channel Partner Insight are designed to honor the partners and vendors that have brought true value and innovation to the managed services market. During a year of unprecedented disruption and change for all businesses across the globe, MSPs have become invaluable allies to large enterprises. With the COVID-19 pandemic forcing organizations to digitally transform their businesses almost overnight, technology has never been a more important asset to continue and further their success. The 2020 Channel Innovation Award winners are the vendors and partners who have provided a lifeline and made a real difference to their customers over the last 12 months.

2nd Watch helps companies migrate to, manage and optimize Amazon Web Services, Microsoft Azure and Google Cloud environments. The firm’s business revolves around six solution areas: Enterprise Cloud Migration, Security and Compliance, Cloud Native and DevOps, Optimization, Data Engineering and Analytics, and Managed Services. This focus sets 2nd Watch apart through architecting and managing client cloud environments that maximize efficiencies and deliver strong business results. 2nd Watch clients typically save 30% or more just by moving to the cloud, and an average of 42% more when 2nd Watch manages the cloud infrastructure for them.

In 2020, 2nd Watch earned a score of 85 in a customer Net Promoter Score survey, a 93% increase over its 2015 NPS score. The company’s customer retention rate has been over 99% the past two years. 2nd Watch’s customers include some of the world’s biggest brands, including Lenovo, Conde Nast, Crate & Barrel and Yamaha.

2nd Watch expanded its services in 2020 in step with enterprise needs and the maturation of the cloud. It launched a data analytics service and fully managed DevOps service, a DevSecOps assessment and strategy service, a cloud disaster recovery service, an on-premise to cloud data migration service, and a hybrid cloud service. 2nd Watch also joined the Google Cloud Partner Advantage Program in 2020 and is building out its Google Cloud practice in response to growing demand for Google Cloud’s Platform in the marketplace. 2nd Watch already has multiple Google Cloud certifications and is actively hiring to support a strong Google Cloud sales pipeline.

“We are grateful to Channel Partner Insight for this award and extremely proud of the work we’re doing on behalf of our clients,” said Jim Nolan, Director of Field Client Services at 2nd Watch. “This award is recognition of our status as a trusted partner to the largest enterprises, many of which accelerated their use of cloud services in 2020 due to conditions created by COVID-19.”

About 2nd Watch

2nd Watch is an AWS Premier Consulting Partner, Google Cloud Partner, and Microsoft Azure Gold Partner, providing professional and managed cloud services to enterprise clients. The company’s subject matter experts and software-enabled services provide companies with tested, proven, and trusted solutions with a focus on six solution areas – Enterprise Cloud Migration, Security and Compliance, Cloud Native and DevOps, Optimization, Data Engineering and Analytics, and Managed Services – allowing them to fully leverage the power of the cloud. 2nd Watch solutions are high performing, robust, increase operational excellence, decrease time to market, accelerate growth and lower risk. 2nd Watch helps enterprises design, deploy and manage cloud solutions and monitors business critical workloads 24×7. The company is headquartered in Seattle, Washington. To learn more about 2nd Watch, visit www.2ndwatch.com.

Media contact:
Kevin Wolf
TGPR
(650) 483-1552
[email protected]

New York, NY, Dec. 14, 2020 (GLOBE NEWSWIRE) — Furnished Quarters is thrilled to announce that its very own Doris Kampf, Senior Director of Global Business Development, has received the award for Salesperson of the Year from international relocation company Graebel. Doris accepted the award on behalf of the company during a virtual Graebel partner meeting with vendors on December 2, 2020. Bill Graebel, Chairman and Chief Executive Officer of Graebel, presented the award.

Graebel is a global services leader in moving, mobility and corporate relocation in over 165 countries worldwide. Furnished Quarters has worked closely with Graebel for over 10 years and Doris was recognized for being a strong strategic partner, delivering exceptional guest service and supporting Graebel’s ability to serve its clients.

“Doris has built such a robust relationship with Graebel during her tenure at Furnished Quarters, and we’re so happy she received this honor,” said Steve Brown, CEO of Furnished Quarters. “She takes great pride in helping her relocation accounts better meet their clients’ needs, and she couldn’t be more deserving of the award.”

“Furnished Quarters continues to think outside the box and be a strategic partner that we’re honored to recognize in a year that has been anything but ordinary,” added Pam Capecci, Vice President Strategic Business Development at Graebel. “Doris and her team are focused on driving innovation and making a difference. We are better together.”

About Graebel Companies

Graebel helps Fortune 500s, Global 100s, and other organizations with absolutely everything involved in relocating their people – from rethinking company policies to getting the VP’s cat through customs. In a world where employees have ever higher expectations and businesses want a higher return on mobility, Graebel delivers a straighter line from A to B, a more inviting experience for everyone, and a new lever for business growth. This comprehensive approach is transforming workforce and workplace mobility in 165 countries across six continents.

About Furnished Quarters

Furnished Quarters is the largest independently owned and operated supplier of global temporary housing, offering over 100,000 fully furnished apartments in more than 800 cities around the world. The company, established in 1998 in New York City by brothers Steven and Gary Brown, currently serves more than 5,500 clients, ranging from top Fortune 500 corporations to small businesses. To learn more about Furnished Quarters, visit furnishedquarters.com.

Connect with us on Facebook: facebook.com/furnishedquarters
Connect with us on LinkedIn: linkedin.com/company/furnished-quarters
Connect with us on Twitter: twitter.com/furnishedq
Connect with us on Instagram: instagram.com/furnishedquarters

Attachments

• Doris
• graebel

Robin Spindel
Furnished Quarters
212.367.9400 ext. 4333
[email protected]

Company Releases Fourth Annual Stewardship Report

Company Receives ‘B’ Score from CDP, Above the Sector, Regional and Global Average

MIAMI, Dec. 14, 2020 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the ”Company”), a leading global cruise company which operates Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises, today published its 2019 Stewardship Report as part of the company’s global sustainability program, Sail & Sustain. The Company is also pleased to announce it has been recognized for its environmental disclosure and transparency by achieving a ‘B’ climate change score from CDP, a global environmental nonprofit which evaluates 9,600 companies worldwide annually. The Company’s ‘B’ score is an improvement to prior year and is higher than the Marine Transport sector average of ‘C’, Global average of ‘C’ and North America regional average of ‘D’.

The 2019 Stewardship Report highlights the Company’s key advancements in Environmental, Social and Governance (“ESG”) since its last published report as well as impactful initiatives underway, including:

• Establishment of the Technology, Environmental, Safety and Security (TESS) Committee of the Company’s Board of Directors to oversee matters related to corporate social responsibility and sustainability.
• Creation of a dedicated ESG department to enhance overall strategy, strengthen ESG disclosures and coordinate closely with departments across the organization including Health, Medical, Safety and Environmental Operations, Human Resources, Legal and Supply Chain.
• Strong focus on reducing single-use plastics through initiatives including Norwegian Cruise Line becoming the first major global cruise company to be plastic water bottle free through its partnership with JUST Goods, Inc.
• Strengthened commitment to maintaining the Company’s culture of diversity, equality and inclusion in the workplace through its partnership with the Florida Diversity Council, diverse hiring initiatives and recent launch of diversity, equality and inclusion online training, including unconscious bias training.
• Relaunched Hope Starts Here hurricane relief campaign in partnership with All Hands and Hearts and donated $3 million of cash and in-kind donations to assist in emergency relief efforts after Hurricane Dorian.
• Continued participation from team members who donated over 1,000 hours giving back to the community through events such as beach clean ups, Habitat for Humanity, and dinner services at the Camillus House Campus emergency housing facility.
• Launched numerous philanthropy initiatives including the Giving Joy campaign which recognized hardworking teachers and the Encore Moments campaign which celebrated everyday heroes.
• Increased spend with diverse vendors in the United States by 36% in 2019 as compared to 2018 as part of the Company’s commitment to facilitate and encourage the growth of small and diverse suppliers.
• Established the Healthy Sail Panel in collaboration with Royal Caribbean Group, a group of 11 leading experts to help inform the cruise industry in the development of new and enhanced cruise health and safety standards in response to the global COVID-19 pandemic.

“Despite the public health challenges we currently face, our commitment to protect and preserve our oceans, the environment and the destinations we visit, while maintaining our culture of diversity, equality and inclusion in the workforce, remains at the very core of our everyday business operations,” said Frank Del Rio, president and chief executive officer of Norwegian Cruise Line Holdings Ltd. “We are proud of our accomplishments to date and remain committed to driving a positive impact on society and the environment through the advancement of our global ESG strategy, while at the same time providing truly exceptional cruise vacation experiences to our guests.”

“Our annual stewardship report provides critical transparency to our key stakeholders around our Sail & Sustain initiatives and we strive for continuous improvement of our ESG disclosures,” said Andrea DeMarco, senior vice president of ESG, Investor Relations and Corporate Communications of Norwegian Cruise Line Holdings Ltd. “We are pleased to be recognized with an above average ‘B’ climate change score by CDP, whose annual environmental disclosure and scoring process is widely regarded as the gold standard of corporate environmental transparency, for our efforts to be a leader in corporate sustainability.”

The 2019 Stewardship Report is part of the company’s global sustainability program, Sail & Sustain, which reflects the Company’s mission to continually improve its sustainability culture through fresh innovation, progressive education and open collaboration. The 2019 Stewardship Report can be found on the Company’s website at http://www.nclhltd.com/Stewardship.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 28 ships with approximately 59,150 berths, these brands offer itineraries to more than 490 destinations worldwide. The Company has nine additional ships scheduled for delivery through 2027.

About the Healthy Sail Panel

Norwegian Cruise Line Holdings Ltd. in collaboration with Royal Caribbean Group established the Healthy Sail Panel (“HSP”), a group of 11 leading experts to help inform the cruise industry in the development of new and enhanced cruise health and safety standards in response to the global COVID-19 pandemic. The HSP, co-chaired by Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration and Governor Mike Leavitt, former Secretary of the U.S. Department of Health and Human Services, consists of globally recognized experts from various disciplines, including public health, infectious disease, biosecurity, hospitality and maritime operations. The panel’s work, including 74 detailed recommendations across five key areas of focus, is informing the Company’s health and safety protocols and has been widely shared with the cruise industry and open to any other industry that could benefit from the HSP’s scientific and medical insights.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this release, including, without limitation, those regarding our business strategy, financial position, results of operations, plans, prospects, actions taken or strategies being considered with respect to our liquidity position, valuation and appraisals of our assets and objectives of management for future operations (including those regarding our charitable, social, supply chain, or environmental programs and goals, expected fleet additions, our voluntary suspension, our ability to weather the impacts of the COVID-19 pandemic and the length of time we can withstand a suspension of voyages, our expectations regarding the resumption of cruise voyages and the timing for such resumption of cruise voyages, the implementation of and effectiveness of our health and safety protocols, operational position, demand for voyages, financing opportunities and extensions, and future cost mitigation and cash conservation efforts and efforts to reduce operating expenses and capital expenditures) are forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward- looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: the spread of epidemics, pandemics and viral outbreaks and specifically, the COVID-19 pandemic, including its effect on the ability or desire of people to travel (including on cruises), which are expected to continue to adversely impact our results, operations, outlook, plans, goals, growth, reputation, cash flows, liquidity, demand for voyages and share price; our ability to comply with the CDC’s Framework for Conditional Sailing Order and to otherwise develop enhanced health and safety protocols to adapt to the current pandemic environment’s unique challenges once operations resume and to otherwise safely resume our operations when conditions allow; coordination and cooperation with the CDC, the federal government and global public health authorities to take precautions to protect the health, safety and security of guests, crew and the communities visited and the implementation of any such precautions; our ability to work with lenders and others or otherwise pursue options to defer, renegotiate or refinance our existing debt profile, near-term debt amortization, newbuild related payments and other obligations and to work with credit card processors to satisfy current or potential future demands for collateral on cash advanced from customers relating to future cruises; our potential future need for additional financing, which may not be available on favorable terms, or at all, and may be dilutive to existing shareholders; our indebtedness and restrictions in the agreements governing our indebtedness that require us to maintain minimum levels of liquidity and otherwise limit our flexibility in operating our business, including the significant portion of assets that are collateral under these agreements; the accuracy of any appraisals of our assets as a result of the impact of COVID-19 or otherwise; our success in reducing operating expenses and capital expenditures and the impact of any such reductions; our guests’ election to take cash refunds in lieu of future cruise credits or the continuation of any trends relating to such election; trends in, or changes to, future bookings and our ability to take future reservations and receive deposits related thereto; the unavailability of ports of call; future increases in the price of, or major changes or reduction in, commercial airline services; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; adverse incidents involving cruise ships; adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; any further impairment of our trademarks, trade names or goodwill; breaches in data security or other disturbances to our information technology and other networks or our actual or perceived failure to comply with requirements regarding data privacy and protection; changes in fuel prices and the type of fuel we are permitted to use and/or other cruise operating costs; mechanical malfunctions and repairs, delays in our shipbuilding program, maintenance and refurbishments and the consolidation of qualified shipyard facilities; the risks and increased costs associated with operating internationally; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our expansion into and investments in new markets; our inability to obtain adequate insurance coverage; pending or threatened litigation, investigations and enforcement actions; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; our inability to recruit or retain qualified personnel or the loss of key personnel or employee relations issues; our reliance on third parties to provide hotel management services for certain ships and certain other services; our inability to keep pace with developments in technology; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under “Risk Factors” in our most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the Securities and Exchange Commission. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 pandemic. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. The above examples are not exhaustive and new risks emerge from time to time. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Andrea DeMarco   (305) 468-2339 [email protected] Jessica John (786) 913-2902

SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller II will be presenting at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020, at 11:00 a.m. PST/2:00 p.m. EST.

During the 10-minute presentation, Huemoeller will discuss AXIM’s COVID-focused research and testing tools, including an update on progress around the Company’s Emergency Use Authorization (EUA) application on its rapid point-of-care COVID-19 neutralizing antibody test. Directly following his presentation, Huemoeller will take questions from a panel of investors and analysts.

AXIM® Biotech CEO John W. Huemoeller II commented: “As we move close to having the first COVID-19 vaccines available in the U.S., our rapid COVID-19 neutralizing antibody test can serve as an easy, quick and relatively inexpensive way for researchers to determine the efficacy of their vaccines. I look forward to presenting on this topic and the other highlights of AXIM’s COVID-focused research during the LD Micro Main Event investor conference.”

To register for the conference, visit ve.mysequire.com/. The LD Micro Main Event investor conference will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

About AXIM® Biotechnologies

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.

Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.

Forward-Looking Statements

The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

CONTACT:

Public Relations Contact:

Kathryn Brown
Account Supervisor
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com

AXIM Corporate Contact Info:

6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422

Investor Relations Contact:

[email protected]

888-759-0844

STRATHROY, Ontario, Dec. 14, 2020 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that it has successfully completed its non-brokered financing of unsecured convertible debentures in the principal amount of Cdn$550,000 (the “Debentures”) to certain individuals, including the Company’s Chief Executive Officer, Melinda Rombouts. The proceeds from the Debentures will be utilized for general working capital purposes.

The Debentures have a two-year term and bear simple interest at a rate of 10% per annum. The principal amount of the Debentures may be converted by the Debentures’ holder at any time into common shares of the Company (“Common Shares”) at a deemed price of $0.06 per Common Share during the first year of the term and $0.10 per Common Share during the second year of the term.

The interest payable under the Debentures shall be paid in cash within five business days of each financial year end or upon notice of early redemption by the Company. The Debentures may be redeemed by the Company prior to the expiry of their term at the option of the Company, subject to payment by the Company of certain specified early redemption payments.

In addition, an aggregate of 4,581,500 share purchase warrants (the “Warrants”) of the Company were issued together with the Debentures (being 8.33 Warrants for each $1.00 principal amount of Debentures). Each Warrant entitles the holder to acquire one Common Share at an exercise price of $0.06 per Common Share for a period of two years from the date of issuance of the Warrant.

“We are very pleased to have completed this Debenture offering in such a short window of time. As the lead investor in the offering, I am confident that the funds raised will enable Eve to continue to flourish as we move to achieving the sales targets and international shipments expected in early 2021. This investment is reflective of the confidence our associates and I have in the Company, its prospects and growth potential,” said Melinda Rombouts, President and Chief Executive Officer of Eve & Co.

No finders’ fees were paid in association with this financing. All securities issued and issuable in connection with the financing are subject to a statutory hold period expiring on April 12, 2021.

Pursuant to the financing, the Chief Executive Officer of the Company acquired Debentures in the aggregate principal amount of $200,000. This issuance of the Debentures and accompanying Warrants to the Chief Executive Officer constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as at the time the transaction was agreed to, neither the fair market value of the subject matter of, or the fair market value of the consideration for, the transaction insofar as it involves interested parties, exceeded 25% of the Company’s market capitalization, pursuant to subsections 5.5(a) and 5.7(1)(a) of 61-101.

The Company also announces the grant of 3,000,000 options to purchase Common Shares (the “Options”) to a director. The Options are exercisable at a price of $0.055 per share, for a term of five years. The terms of the Options granted on December 11, 2020 are in accordance with the Company’s stock option plan.

ABOUT EVE & CO

Eve & Co, through its wholly-owned subsidiary NMC, holds cultivation and processing licences under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received its European Union certificate of Good Manufacturing Practice. NMC was Canada’s first female-founded licensed producer of medicinal marijuana and received its cultivation licence from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 square foot greenhouse located in Strathroy, Ontario. 

The Company’s website can be visited at www.evecannabis.ca.

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur, and include, but are not limited to, the negative of these words or other variations on these words or comparable terminology. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Forward-looking statements contained in this release including statements with respect to the proposed use of proceeds of the financing and potential conversion/exercise of the Debentures and Warrants, amongst other matters. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s management’s discussion and analysis dated November 26, 2020 (the “MD&A”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at 

www.sedar.com

. The Company cautions that the list of risks, uncertainties and other factors described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

For further information, please contact:

Melinda Rombouts
President and Chief Executive Officer Eve & Co Incorporated
Telephone: (855) 628-6337

Rory Taylor
Interim Chief Financial Officer Eve & Co Incorporated
Telephone: (855) 628-6337